Merus N.V.
MRUSDelisted Dec 30, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001651311
Merus N.V. was delisted on Dec 30, 2025; its insiders filed their last Form 4 on Dec 30, 2025; 268 institutions reported holding it in 13F filings for Q3 2025, worth $6.70B in total; Soros Fund Management was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Merus N.V. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Merus N.V., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Genmab A/S | 10% Owner | 0Indirect | Dec 30, 2025 | 4 |
| Perry Gregory D | Chief Financial Officer & PFO | – | Dec 12, 2025 | 1 |
| Gowen Maxine | Director | – | Dec 12, 2025 | 1 |
| Iwicki Mark T | Director | 0 | Dec 12, 2025 | 1 |
| Pucci Paolo | Director | – | Dec 12, 2025 | 1 |
| Mehra Anand | Director | – | Dec 12, 2025 | 1 |
| Sandor Victor | Director | – | Dec 12, 2025 | 1 |
| Haddock Jason | Director | – | Dec 12, 2025 | 1 |
| Lundberg Sven Ante | President, CEO & PEO | 0Indirect | Dec 12, 2025 | 2 |
| Kanavy Len | Director | – | Dec 12, 2025 | 1 |
| Silverman Peter B. | COO & GC | 0 | Dec 12, 2025 | 1 |
| Shuman Harry | VP Controller, PAO | 0 | Dec 12, 2025 | 3 |
| Zohren Fabian | Chief Medical Officer | – | Dec 12, 2025 | 1 |
| Liu Hui | EVP, CBO & Head of Merus US | 156,016 | May 9, 2024 | 0 |
| Joe Andrew | SVP, CMO | – | May 9, 2024 | 0 |
| Bakker Lex | SVP, Chief Development Officer | 15,668 | Feb 2, 2022 | 0 |
| de Kruif John | SVP & Chief Technology Officer | 15,282 | Feb 2, 2022 | 0 |
| Geuijen Cecile A W | SVP & Chief Scientific Officer | – | Feb 2, 2022 | 0 |
| Biotechnology Value Fund L P | Other: See Explanation of Responses | 232,747 | Oct 8, 2021 | 0 |
| BVF Partners L P | 10% Owner | 232,747 | Oct 8, 2021 | 0 |
| BVF Inc | 10% Owner | 232,747 | Oct 8, 2021 | 0 |
| Biotechnology Value Fund II LP | Other: See Explanation of Responses | 232,747 | Oct 8, 2021 | 0 |
| Lampert Mark N | 10% Owner | 232,747 | Oct 8, 2021 | 0 |
| Biotechnology Value Trading Fund OS LP | Other: See Explanation of Responses | 232,747 | Oct 8, 2021 | 0 |
| BVF Partners OS Ltd. | Other: See Explanation of Responses | 232,747 | Oct 8, 2021 | 0 |
| BVF I GP LLC | Other: See Explanation of Responses | 232,747 | Oct 8, 2021 | 0 |
| BVF II GP LLC | Other: See Explanation of Responses | 232,747 | Oct 8, 2021 | 0 |
| BVF GP Holdings LLC | Other: See Explanation of Responses | 232,747 | Oct 8, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 30, 2025 (view filing) | Dec 26-29 | 4 days | Genmab A/S10% Owner | PPurchaseCommon Shares, nominal value EUR 0.09 per share | +1.06M | $97.00 | +$102.4M | +1.4%73.9M after | 2 lots |
| Dec 30, 2025 (view filing) | Dec 29 | 1 day | Genmab A/S10% Owner | PPurchaseCommon Shares, nominal value EUR 0.09 per share | −75.9M | $97.00 | −$7.36B | −100.0%0 after | |
| Dec 29, 2025 (view filing) | Dec 22-26 | 7 days | Genmab A/S10% Owner | PPurchaseCommon Shares, nominal value EUR 0.09 per share | +815.4K | $97.00 | +$79.1M | +1.1%72.8M after | 4 lots |
| Dec 22, 2025 (view filing) | Dec 18-19 | 4 days | Genmab A/S10% Owner | PPurchaseCommon Shares, nominal value EUR 0.09 per share | +278.4K | $97.00 | +$27.0M | +0.4%72.0M after | 2 lots |
| Dec 18, 2025 (view filing) | Dec 16-17 | 2 days | Genmab A/S10% Owner | PPurchaseCommon Shares, nominal value EUR 0.09 per share | +271.5K | $97.00 | +$26.3M | +0.4%71.7M after | 2 lots |
| Dec 10, 2025 (view filing) | Nov 26 | 14 daysLate | Shuman HarryVP Controller, PAO | SSale | −1.70K | $96.10 | −$163.4K | −13.4%11.0K after | |
| Nov 28, 2025 (view filing) | Nov 25 | 3 days | Shuman HarryVP Controller, PAO | SSale | −8.30K | $95.92 | −$796.1K | −43.0%11.0K after | |
| Jul 18, 2025 (view filing) | Jul 17 | 1 day | Silverman Peter B.COO & GC | SSale | −25.0K | $60.00 | −$1.50M | −100.0%0 after | 10b5-1 |
| Jul 11, 2025 (view filing) | Jul 9-10 | 2 days | Silverman Peter B.COO & GC | SSale | −23.5K | $55.00 | −$1.29M | −100.0%0 after | 2 lots10b5-1 |
| Jun 24, 2025 (view filing) | Jun 20 | 4 days | Silverman Peter B.COO & GC | SSale | −34.0K | $52.76 | −$1.79M | −100.0%0 after | 10b5-1 |
| Mar 25, 2025 (view filing) | Mar 21 | 4 days | Shuman HarryVP Controller, PAO | SSale | −4.00K | $48.50 | −$194.0K | −26.7%11.0K after | 2 lots |
| Aug 22, 2024 (view filing) | Aug 20-21 | 2 days | Shuman HarryVP Controller, PAO | SSale | −5.00K | $54.00 | −$270.0K | −41.7%7.00K after | 2 lots |
| Jun 28, 2024 (view filing) | Jun 27 | 1 day | Silverman Peter B.COO & GC | SSale | −10.0K | $60.00 | −$600.0K | −100.0%0 after | 10b5-1 |
| Jun 20, 2024 (view filing) | Jun 17 | 3 days | Silverman Peter B.COO & GC | SSale | −62.0K | $56.52 | −$3.50M | −100.0%0 after | 10b5-1 |
| Jun 12, 2024 (view filing) | Jun 10-12 | 2 days | Shuman HarryVP Controller, PAO | SSale | −8.30K | $57.28 | −$475.5K | −54.2%7.00K after | 2 lots |
| Jun 6, 2024 (view filing) | Jun 4 | 2 days | Shuman HarryVP Controller, PAO | SSale | −6.00K | $52.90 | −$317.4K | −46.1%7.00K after | 2 lots |
| Dec 20, 2023 (view filing) | Dec 19 | 1 day | Shuman HarryVP Controller, PAO | SSale | −115 | $26.68 | −$3.07K | −1.6%7.00K after | |
| Dec 18, 2023 (view filing) | Dec 15 | 3 days | Silverman Peter B.COO & GC | SSale | −22.4K | $25.00 | −$559.6K | −100.0%0 after | |
| Dec 12, 2023 (view filing) | Dec 8 | 4 days | Shuman HarryVP Controller, PAO | SSale | −250 | $24.44 | −$6.11K | −3.4%7.12K after | |
| Dec 4, 2023 (view filing) | Dec 1 | 3 days | Shuman HarryVP Controller, PAO | SSale | −575 | $24.58 | −$14.1K | −7.2%7.37K after | |
| Jun 1, 2023 (view filing) | Jun 1 | Same day | Shuman HarryVP Controller, PAO | SSale | −575 | $21.48 | −$12.4K | −9.6%5.44K after | |
| Dec 14, 2022 (view filing) | Dec 13 | 1 day | Shuman HarryVP Controller, PAO | SSale | −168 | $13.85 | −$2.33K | −4.6%3.52K after | |
| Dec 1, 2022 (view filing) | Dec 1 | Same day | Shuman HarryVP Controller, PAO | SSale | −575 | $15.35 | −$8.83K | −13.5%3.69K after | |
| Nov 3, 2022 (view filing) | Nov 3 | Same day | Lundberg Sven AntePresident, CEO & PFO | PPurchase | +14.7K | $14.38 | +$211.5K | +56.8%40.6K after | |
| Aug 29, 2022 (view filing) | Aug 25 | 4 days | Shuman HarryVP Controller, PAO | SSale | −165 | $24.33 | −$4.01K | −8.6%1.76K after | |
| Aug 23, 2022 (view filing) | Aug 22 | 1 day | Lundberg Sven AntePresident, CEO & PFO | PPurchase | +5.83K | $22.92 | +$133.5K | +29.1%25.9K after | From original |
| Aug 22, 2022 (view filing) | Aug 19 | 3 days | Lundberg Sven AntePresident, CEO & PFO | PPurchase | +704 | $22.99 | +$16.2K | +3.6%20.0K after | |
| Jul 13, 2022 (view filing) | Jul 12 | 1 day | Lundberg Sven AntePresident, CEO & PFO | PPurchase | +4.34K | $22.97 | +$99.7K | +28.9%19.3K after | |
| Jun 3, 2022 (view filing) | Jun 1 | 2 days | Shuman HarryVP Controller, PAO | SSale | −575 | $18.31 | −$10.5K | −23.0%1.93K after | |
| Mar 11, 2022 (view filing) | Mar 10 | 1 day | Silverman Peter B.EVP, GC and Head of Utrecht | SSale | −60.0K | $26.95 | −$1.62M | −100.0%0 after | |
| Oct 8, 2021 (view filing)9:24 PM ET | Oct 7-8 | 1 day | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | SSaleCommon Shares, (euro)0.09 nominal value per share | −1.13M | $27.56 | −$31.2M | −83.0%232.7K after | 6 lots |
| Aug 16, 2021 (view filing) | Aug 12 | 4 days | de Kruif JohnSVP & Chief Technology Officer | SSale | −2.79K | $19.34 | −$53.9K | −15.4%15.3K after | |
| Jul 7, 2021 (view filing)4:49 PM ET | Jul 2 | 5 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | SSaleCommon Shares, (euro)0.09 nominal value per share | −2.19M | $20.75 | −$45.4M | −87.5%311.2K after | 3 lots |
| Jul 6, 2021 (view filing) | Jul 1 | 5 days | Bakker LexSVP, Chief Development Officer | SSale | −3.86K | $21.05 | −$81.3K | −30.8%8.67K after | 3 lots |